Hospital Variations in Time-To-Crisis-Resolution Among Children and Adolescents With Sickle Cell Disease

Chris A Rees; Dunia Hatabah; Rawan Korman; Fahd Ahmad; Gladstone Airewele; Bolanle Akinsola; Noor Alzraikat; Nitya Bakshi; David C Brousseau; Kathleen Brown; Andrew D Campbell; T Charles Casper; Todd P Chang; Corrie E Chumpitazi; Daniel Cohen; Keli D Coleman; Andrea T Cruz; Christopher Denton; Angela Ellison; Melanie E Fields; Monica Harding; Sara Leibovich; Allison Remiker; Nidhi V Singh; Alexis A Thompson; Elliott Vichinsky; Anthony Villella; Bridget Wynn; Carlton Dampier; Claudia R Morris; Pediatric Emergency Care Research Network (PECARN)

doi:10.1002/ajh.70129

Hospital Variations in Time-To-Crisis-Resolution Among Children and Adolescents With Sickle Cell Disease

Am J Hematol. 2026 Jan;101(1):206-212. doi: 10.1002/ajh.70129. Epub 2025 Nov 5.

Authors

Chris A Rees^{1

2}, Dunia Hatabah¹, Rawan Korman¹, Fahd Ahmad³, Gladstone Airewele⁴, Bolanle Akinsola^{1

2}, Noor Alzraikat¹, Nitya Bakshi⁵, David C Brousseau⁶, Kathleen Brown⁷, Andrew D Campbell⁷, T Charles Casper⁸, Todd P Chang⁹, Corrie E Chumpitazi¹⁰, Daniel Cohen¹¹, Keli D Coleman¹², Andrea T Cruz⁴, Christopher Denton⁹, Angela Ellison¹³, Melanie E Fields³, Monica Harding¹⁴, Sara Leibovich¹⁵, Allison Remiker¹², Nidhi V Singh⁴, Alexis A Thompson¹³, Elliott Vichinsky^{16

17}, Anthony Villella¹¹, Bridget Wynn^{1

2}, Carlton Dampier¹⁸, Claudia R Morris^{1

2}; Pediatric Emergency Care Research Network (PECARN)

Affiliations

¹ Department of Pediatrics, Division of Pediatric Emergency Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
² Division of Pediatric Emergency Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
³ Division of Pediatric Emergency Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
⁴ Texas Children's Cancer and Hematology Centers, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas, USA.
⁵ Division of Pediatric Hematology-Oncology, Yale School of Medicine, New Haven, Connecticut, USA.
⁶ Department of Pediatrics, Nemours Children's Health Delaware and the Sidney Kimmel Medical College at Thomas Jefferson University, Wilmington, Delaware, USA.
⁷ Division of Emergency Medicine, Children's National Hospital and The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
⁸ Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.
⁹ Division of Pediatric Emergency Medicine, Children's Hospital Los Angeles and Keck School of Medicine of the University of Southern California, California, Los Angeles, USA.
¹⁰ Division of Emergency Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
¹¹ Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
¹² Section of Emergency Medicine, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, Wisconsin, USA.
¹³ Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
¹⁴ Division of Pediatric Critical Care, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA.
¹⁵ Department of Emergency Medicine, University of California, San Francisco, California, USA.
¹⁶ Center for Maternal-Fetal Precision Medicine, University of California, San Francisco, California, USA.
¹⁷ Department of Pediatrics and, UCSF-Benioff Children's Hospital-Oakland, Oakland, California, USA.
¹⁸ Department of Pediatrics, Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, Georgia, USA.

Abstract

Analysis of the placebo cohort in the STArT trial shows that patient characteristics and hospital site strongly influence time-to-crisis-resolution and total opioid use in children and young adults with sickle cell disease, highlighting the need to account for these factors in the design of future clinical trials.

Keywords: arginine; sickle cell disease; sickle cell disease treatment with arginine therapy (STArT); time‐to‐crisis‐resolution; vaso‐occlusive pain episodes.

Publication types

Letter

MeSH terms

Adolescent
Adult
Analgesics, Opioid* / therapeutic use
Anemia, Sickle Cell* / complications
Anemia, Sickle Cell* / drug therapy
Anemia, Sickle Cell* / therapy
Child
Child, Preschool
Female
Hospitals*
Humans
Male
Time Factors
Young Adult

Substances

Analgesics, Opioid

Abstract

Publication types

MeSH terms

Substances

Grants and funding